[go: up one dir, main page]

MX2019000346A - Metodos y composiciones para el tratamiento del cancer. - Google Patents

Metodos y composiciones para el tratamiento del cancer.

Info

Publication number
MX2019000346A
MX2019000346A MX2019000346A MX2019000346A MX2019000346A MX 2019000346 A MX2019000346 A MX 2019000346A MX 2019000346 A MX2019000346 A MX 2019000346A MX 2019000346 A MX2019000346 A MX 2019000346A MX 2019000346 A MX2019000346 A MX 2019000346A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
compositions
methods
polypeptide
Prior art date
Application number
MX2019000346A
Other languages
English (en)
Inventor
Soucek Laura
Jauset González Toni
- Eve Beaulieu Marie
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Publication of MX2019000346A publication Critical patent/MX2019000346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un polipéptido que comprende o que consiste en el polipéptido de SEQ ID NO: 1 en el que el residuo X en la posición 89 de SEQ ID NO: 1 no es una cisteína, o a una variante funcionalmente equivalente de dichopolipéptido en el que el residuo X en la posición 89 de SEQ ID NO: 1 no es una cisteína y a su uso en medicina, particularmente en la prevención y/o el tratamiento del cáncer.
MX2019000346A 2016-07-15 2017-07-17 Metodos y composiciones para el tratamiento del cancer. MX2019000346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382339.6A EP3269734A1 (en) 2016-07-15 2016-07-15 Methods and compositions for the treatment of cancer
PCT/EP2017/067998 WO2018011433A1 (en) 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019000346A true MX2019000346A (es) 2019-04-01

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000346A MX2019000346A (es) 2016-07-15 2017-07-17 Metodos y composiciones para el tratamiento del cancer.

Country Status (21)

Country Link
US (1) US11427621B2 (es)
EP (2) EP3269734A1 (es)
JP (1) JP7090593B2 (es)
KR (1) KR102232500B1 (es)
CN (1) CN109563151B (es)
AU (1) AU2017295071B2 (es)
BR (1) BR112019000732A2 (es)
EA (1) EA201990298A1 (es)
ES (1) ES2985967T3 (es)
HR (1) HRP20241153T1 (es)
HU (1) HUE067973T2 (es)
IL (1) IL264176B2 (es)
MA (1) MA45675B1 (es)
MD (1) MD3484913T2 (es)
MX (1) MX2019000346A (es)
PL (1) PL3484913T3 (es)
RS (1) RS65983B1 (es)
SG (1) SG11201900021PA (es)
SM (1) SMT202400360T1 (es)
WO (1) WO2018011433A1 (es)
ZA (1) ZA201900960B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
WO2020041297A1 (en) * 2018-08-20 2020-02-27 Helix Nanotechnologies, Inc. Methods and compositions for rna expression of myc inhibitors
US20220152179A1 (en) * 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
WO2021208787A1 (zh) * 2020-04-15 2021-10-21 徐荣臻 用于筛选药物的靶标多肽和筛选方法
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment
EP4446742A1 (en) 2023-04-14 2024-10-16 Peptomyc, S.L. Method for assessing or monitoring the response to a cancer treatment
EP4473974A1 (en) * 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
CA2140343A1 (en) 1992-07-17 1994-02-03 Sean M. Sullivan Method and reagent for treatment of animal diseases
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5942433A (en) * 1995-07-31 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9241920B2 (en) 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
EP3484913B1 (en) 2024-07-03
PL3484913T3 (pl) 2025-01-07
JP2019525753A (ja) 2019-09-12
MD3484913T2 (ro) 2024-10-31
EP3484913A1 (en) 2019-05-22
CA3029781A1 (en) 2018-01-18
HUE067973T2 (hu) 2024-11-28
US20200247857A1 (en) 2020-08-06
SMT202400360T1 (it) 2024-11-15
CN109563151A (zh) 2019-04-02
US11427621B2 (en) 2022-08-30
HRP20241153T1 (hr) 2024-11-22
IL264176A (en) 2019-02-28
RS65983B1 (sr) 2024-10-31
EP3269734A1 (en) 2018-01-17
KR20190032427A (ko) 2019-03-27
IL264176B2 (en) 2023-07-01
MA45675A (fr) 2021-04-21
EA201990298A1 (ru) 2019-06-28
AU2017295071B2 (en) 2022-06-09
MA45675B1 (fr) 2024-07-31
ZA201900960B (en) 2020-05-27
IL264176B1 (en) 2023-03-01
WO2018011433A1 (en) 2018-01-18
EP3484913C0 (en) 2024-07-03
AU2017295071A1 (en) 2019-01-31
KR102232500B1 (ko) 2021-03-26
JP7090593B2 (ja) 2022-06-24
SG11201900021PA (en) 2019-01-30
BR112019000732A2 (pt) 2019-07-30
ES2985967T3 (es) 2024-11-08
CN109563151B (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
MY187486A (en) Cysteine protease
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12019550265A1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2019002284A (es) Sistemas de deposito que comprenden acetato de glatiramer.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MX2016013589A (es) Composiciones que comprenden derivados de osteopontina para la inhibicion del crecimiento de pelo.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2016010431A (es) Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa.
PH12018550215A1 (en) Product for use against development or growth of fungus
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
MX2019001320A (es) Composicion y uso de un peptido.